Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers

Author： Takahashi Yuri   Miyoshi Yasuo   Morimoto Koji   Taguchi Tetsuya   Tamaki Yasuhiro   Noguchi Shinzaburo  

Publisher： Springer Publishing Company

ISSN： 0171-5216

Source： Journal of Cancer Research and Clinical Oncology, Vol.133, Iss.8, 2007-08, pp. : 501-509

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor

By Kwasny W.  

Breast Cancer Research and Treatment, Vol. 63, Iss. 3, 2000-10 ,pp. : 235-241

Springer Publishing Company

Access to resources Recommend Favorite

Lonidamine plus Epirubicin and Cyclophosphamide in Advanced Breast Cancer. A Phase II Study

By Gardin G.   Barone C.   Nascimben O.   Ianniello G.   Sturba F.   Contu A.   Pronzato P.   Rosso R.  

European Journal of Cancer, Vol. 32, Iss. 1, 1996-01 ,pp. : 176-177

Elsevier

Access to resources Recommend Favorite

Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide

By Andersen Kenneth Geving   Jensen Maj-Britt   Kehlet Henrik   Gärtner Rune   Eckhoff Lise   Kroman Niels  

Acta Oncologica, Vol. 51, Iss. 8, 2012-11 ,pp. : 1036-1044

Informa Healthcare

Access to resources Recommend Favorite

Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer

By Chen Xiaosong   Ye Guolin   Zhang Chenfang   Li Xinzheng   Chen Yiding   Xie Xiaohong   Zheng Hong   Cao Yali   Wu Kejin   Ni Duo   Tang Jinhai   Wei Ziguo   Shen Kunwei  

Breast Cancer Research and Treatment, Vol. 142, Iss. 3, 2013-12 ,pp. : 549-558

Springer Publishing Company

Access to resources Recommend Favorite

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

By Ohno S.   Chow L.   Sato N.   Masuda N.   Sasano H.   Takahashi F.   Bando H.   Iwata H.   Morimoto T.   Kamigaki S.   Nakayama T.   Nakamura S.   Kuroi K.   Aogi K.   Kashiwaba M.   Yamashita H.   Hisamatsu K.   Ito Y.   Yamamoto Y.   Ueno T.   Fakhrejahani E.   Yoshida N.   Toi M.  

Breast Cancer Research and Treatment, Vol. 142, Iss. 1, 2013-11 ,pp. : 69-80

Springer Publishing Company

Access to resources Recommend Favorite